{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:25:49Z","timestamp":1794623149278,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-70663-1","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:44:43Z","timestamp":1774403083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader"],"prefix":"10.1038","volume":"17","author":[{"given":"Monica C.","family":"Rodrigo-Brenni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper C.","family":"Komen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaith M.","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-9898","authenticated-orcid":false,"given":"Natacha","family":"Bohin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Adomavicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Blaho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"B\u00f6rjesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-922X","authenticated-orcid":false,"given":"Gavin W.","family":"Collie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"De Donatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-5816","authenticated-orcid":false,"given":"Frederik","family":"Eisele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1605-4137","authenticated-orcid":false,"given":"Ning","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gohlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5301-1078","authenticated-orcid":false,"given":"Christoph","family":"Grebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Kankkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7818-671X","authenticated-orcid":false,"given":"Praveen","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1866-4193","authenticated-orcid":false,"given":"Emilyanne","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Madeyski-Bengtson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Miele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Nevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Overman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Pachl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Pathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W. D.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6569-9025","authenticated-orcid":false,"given":"Christopher","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-7501","authenticated-orcid":false,"given":"Andy","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Purvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Rasmusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Ian","family":"Storer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacovos N.","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"70663_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/tera.1420380303","volume":"38","author":"W Lenz","year":"1988","unstructured":"Lenz, W. A short history of thalidomide embryopathy. Teratology 38, 203\u2013215 (1988).","journal-title":"Teratology"},{"key":"70663_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/bdrc.21096","volume":"105","author":"N Vargesson","year":"2015","unstructured":"Vargesson, N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res. C Embryo Today 105, 140\u2013156 (2015).","journal-title":"Birth Defects Res. C Embryo Today"},{"key":"70663_CR3","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau, P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28, iv52\u2013iv61 (2017).","journal-title":"Ann. Oncol."},{"key":"70663_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","volume":"14","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat. Chem. Biol. 14, 981\u2013987 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"70663_CR5","doi-asserted-by":"publisher","first-page":"eLife.38430","DOI":"10.7554\/eLife.38430","volume":"7","author":"KA Donovan","year":"2018","unstructured":"Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife 7, eLife.38430 (2018).","journal-title":"Elife"},{"key":"70663_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350 (2010).","journal-title":"Science"},{"key":"70663_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/jmg.40.7.473","volume":"40","author":"J Kohlhase","year":"2003","unstructured":"Kohlhase, J. et al. Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomide embryopathy. J. Med. Genet. 40, 473\u2013478 (2003).","journal-title":"J. Med. Genet."},{"key":"70663_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/ng1707","volume":"38","author":"K Koshiba-Takeuchi","year":"2006","unstructured":"Koshiba-Takeuchi, K. et al. Cooperative and antagonistic interactions between Sall4 and Tbx5 pattern the mouse limb and heart. Nat. Genet. 38, 175\u2013183 (2006).","journal-title":"Nat. Genet."},{"key":"70663_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"70663_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"70663_CR11","doi-asserted-by":"publisher","first-page":"eaat0572","DOI":"10.1126\/science.aat0572","volume":"362","author":"QL Sievers","year":"2018","unstructured":"Sievers, Q. L. et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362, eaat0572 (2018).","journal-title":"Science"},{"key":"70663_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-biochem-032620-104421","volume":"91","author":"AD Cowan","year":"2022","unstructured":"Cowan, A. D. & Ciulli, A. Driving E3 ligase substrate specificity for targeted protein degradation: lessons from nature and the laboratory. Annu. Rev. Biochem. 91, 295\u2013319 (2022).","journal-title":"Annu. Rev. Biochem."},{"key":"70663_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"70663_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41594-020-0438-0","volume":"27","author":"T Wu","year":"2020","unstructured":"Wu, T. et al. Targeted protein degradation as a powerful research tool in basic biology and drug target discovery. Nat. Struct. Mol. Biol. 27, 605\u2013614 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"70663_CR15","doi-asserted-by":"publisher","DOI":"10.1039\/D4MD00769G","author":"J Scott","year":"2024","unstructured":"Scott, J., Michaelides, I. & Schade, M. Property-based optimisation of PROTACs. RSC Med. Chem. https:\/\/doi.org\/10.1039\/D4MD00769G (2024).","journal-title":"RSC Med. Chem."},{"key":"70663_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3\u201326 (2001).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"70663_CR17","doi-asserted-by":"publisher","first-page":"103917","DOI":"10.1016\/j.drudis.2024.103917","volume":"29","author":"G Apprato","year":"2024","unstructured":"Apprato, G. et al. Exploring the chemical space of orally bioavailable PROTACs. Drug Discov. Today 29, 103917 (2024).","journal-title":"Drug Discov. Today"},{"key":"70663_CR18","doi-asserted-by":"publisher","first-page":"103865","DOI":"10.1016\/j.drudis.2023.103865","volume":"29","author":"W Yang","year":"2024","unstructured":"Yang, W., Saboo, S., Zhou, L., Askin, S. & Bak, A. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges. Drug Discov. Today 29, 103865 (2024).","journal-title":"Drug Discov. Today"},{"key":"70663_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","volume":"61","author":"I Churcher","year":"2018","unstructured":"Churcher, I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?. J. Med. Chem. 61, 444\u2013452 (2018).","journal-title":"J. Med. Chem."},{"key":"70663_CR20","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1111\/bph.15014","volume":"177","author":"K Moreau","year":"2020","unstructured":"Moreau, K. et al. Proteolysis-targeting chimeras in drug development: a safety perspective. Br. J. Pharmacol. 177, 1709\u20131718 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"70663_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods 17, 41\u201344 (2020).","journal-title":"Nat. Methods"},{"key":"70663_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41587-021-00860-4","volume":"39","author":"CB Messner","year":"2021","unstructured":"Messner, C. B. et al. Ultra-fast proteomics with scanning SWATH. Nat. Biotechnol. 39, 846\u2013854 (2021).","journal-title":"Nat. Biotechnol."},{"key":"70663_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1021\/acs.jmedchem.1c01832","volume":"65","author":"M Teng","year":"2022","unstructured":"Teng, M. et al. Development of PDE6D and CK1alpha degraders through chemical derivatization of FPFT-2216. J. Med. Chem. 65, 747\u2013756 (2022).","journal-title":"J. Med. Chem."},{"key":"70663_CR24","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535, 252\u2013257 (2016).","journal-title":"Nature"},{"key":"70663_CR25","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1021\/acs.jmedchem.7b01655","volume":"61","author":"CE Powell","year":"2018","unstructured":"Powell, C. E. et al. Chemically induced degradation of anaplastic lymphoma kinase (ALK). J. Med. Chem. 61, 4249\u20134255 (2018).","journal-title":"J. Med. Chem."},{"key":"70663_CR26","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1177\/0091270009335001","volume":"49","author":"WL Dahut","year":"2009","unstructured":"Dahut, W. L. et al. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J. Clin. Pharmacol. 49, 650\u2013660 (2009).","journal-title":"J. Clin. Pharmacol."},{"key":"70663_CR27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1182\/blood-2009-05-221077","volume":"115","author":"R Pal","year":"2010","unstructured":"Pal, R. et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 115, 605\u2013614 (2010).","journal-title":"Blood"},{"key":"70663_CR28","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","volume":"132","author":"EC Fink","year":"2018","unstructured":"Fink, E. C. et al. Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132, 1535\u20131544 (2018).","journal-title":"Blood"},{"key":"70663_CR29","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/bloodadvances.2017010348","volume":"2","author":"S Li","year":"2018","unstructured":"Li, S. et al. IMiD compounds affect CD34(+) cell fate and maturation via CRBN-induced IKZF1 degradation. Blood Adv. 2, 492\u2013504 (2018).","journal-title":"Blood Adv."},{"key":"70663_CR30","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1021\/tx9801817","volume":"11","author":"M Reist","year":"1998","unstructured":"Reist, M., Carrupt, P. A., Francotte, E. & Testa, B. Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem. Res. Toxicol. 11, 1521\u20131528 (1998).","journal-title":"Chem. Res. Toxicol."},{"key":"70663_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jsb.2014.10.010","volume":"188","author":"MD Hartmann","year":"2014","unstructured":"Hartmann, M. D. et al. Thalidomide mimics uridine binding to an aromatic cage in cereblon. J. Struct. Biol. 188, 225\u2013232 (2014).","journal-title":"J. Struct. Biol."},{"key":"70663_CR32","unstructured":"Borjesson, U. et al. Synthesis of heterocyclic substituted pyrimidine anticancer agents. WO2022069520 (2022)."},{"key":"70663_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1021\/acsmedchemlett.2c00436","volume":"14","author":"JA Jarusiewicz","year":"2023","unstructured":"Jarusiewicz, J. A. et al. Phenyl dihydrouracil: an alternative cereblon binder for PROTAC design. ACS Med. Chem. Lett. 14, 141\u2013145 (2023).","journal-title":"ACS Med. Chem. Lett."},{"key":"70663_CR34","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1021\/acs.jmedchem.2c01941","volume":"66","author":"H Xie","year":"2023","unstructured":"Xie, H. et al. Development of substituted phenyl dihydrouracil as the novel achiral cereblon ligands for targeted protein degradation. J. Med. Chem. 66, 2904\u20132917 (2023).","journal-title":"J. Med. Chem."},{"key":"70663_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4155\/fmc.12.208","volume":"5","author":"KD Freeman-Cook","year":"2013","unstructured":"Freeman-Cook, K. D., Hoffman, R. L. & Johnson, T. W. Lipophilic efficiency: the most important efficiency metric in medicinal chemistry. Future Med. Chem. 5, 113\u2013115 (2013).","journal-title":"Future Med. Chem."},{"key":"70663_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","volume":"9","author":"AL Hopkins","year":"2004","unstructured":"Hopkins, A. L., Groom, C. R. & Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9, 430\u2013431 (2004).","journal-title":"Drug Discov. Today"},{"key":"70663_CR37","unstructured":"Astles, P. & Scott, J. Preparation of bifunctional PROTAC degraders of androgen receptors. WO2024189488 (2024)."},{"key":"70663_CR38","unstructured":"Packer, M. J. et al. Preparation of nitrogen-containing heterocyclic compounds and their use in treating cancer. WO2023139199 (2023)."},{"key":"70663_CR39","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067\u20131073 (2010).","journal-title":"Nature"},{"key":"70663_CR40","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1021\/acsmedchemlett.3c00314","volume":"14","author":"MP Plesniak","year":"2023","unstructured":"Plesniak, M. P. et al. Rapid PROTAC discovery platform: nanomole-scale array synthesis and direct screening of reaction mixtures. ACS Med. Chem. Lett. 14, 1882\u20131890 (2023).","journal-title":"ACS Med. Chem. Lett."},{"key":"70663_CR41","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","volume":"22","author":"J Lu","year":"2015","unstructured":"Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755\u2013763 (2015).","journal-title":"Chem. Biol."},{"key":"70663_CR42","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904\u2013917 (2011).","journal-title":"Cell"},{"key":"70663_CR43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","volume":"64","author":"V Oleinikovas","year":"2024","unstructured":"Oleinikovas, V., Gainza, P., Ryckmans, T., Fasching, B. & Thom\u00e4, N. H. From thalidomide to rational molecular glue design for targeted protein degradation. Annu. Rev. Pharmacol. Toxicol. 64, 291\u2013312 (2024).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"70663_CR44","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.3324\/haematol.2018.188227","volume":"103","author":"A Liu","year":"2018","unstructured":"Liu, A. et al. Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation. Haematologica 103, 1688\u20131697 (2018).","journal-title":"Haematologica"},{"key":"70663_CR45","doi-asserted-by":"publisher","first-page":"e153014","DOI":"10.1172\/JCI153014","volume":"132","author":"RA Campbell","year":"2022","unstructured":"Campbell, R. A. et al. IFITM3 regulates fibrinogen endocytosis and platelet reactivity in nonviral sepsis. J. Clin. Invest. 132, e153014 (2022).","journal-title":"J. Clin. Invest."},{"key":"70663_CR46","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1001\/jama.296.21.2558-c","volume":"296","author":"CL Bennett","year":"2006","unstructured":"Bennett, C. L. et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296, 2558\u20132560 (2006).","journal-title":"JAMA"},{"key":"70663_CR47","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2006-01-0154","volume":"108","author":"JA Zonder","year":"2006","unstructured":"Zonder, J. A. et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108, 403 (2006).","journal-title":"Blood"},{"key":"70663_CR48","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.chembiol.2024.01.003","volume":"31","author":"S Ichikawa","year":"2024","unstructured":"Ichikawa, S. et al. The cyclimids: degron-inspired cereblon binders for targeted protein degradation. Cell Chem. Biol. 31, 1162\u20131175 e1110 (2024).","journal-title":"Cell Chem. Biol."},{"key":"70663_CR49","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","volume":"16","author":"TM Nguyen","year":"2024","unstructured":"Nguyen, T. M. et al. Proteolysis-targeting chimeras with reduced off-targets. Nat. Chem. 16, 218\u2013228 (2024).","journal-title":"Nat. Chem."},{"key":"70663_CR50","doi-asserted-by":"publisher","first-page":"7042","DOI":"10.1021\/acs.jmedchem.9b00516","volume":"62","author":"H Wu","year":"2019","unstructured":"Wu, H. et al. Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity. J. Med. Chem. 62, 7042\u20137057 (2019).","journal-title":"J. Med. Chem."},{"key":"70663_CR51","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1021\/acschembio.5c00751","volume":"20","author":"PJ Brennan","year":"2025","unstructured":"Brennan, P. J. et al. Orthogonal IMiD-degron pairs induce selective protein degradation in cells. ACS Chem. Biol. 20, 2025\u20132843 (2025).","journal-title":"ACS Chem. Biol."},{"key":"70663_CR52","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1021\/acs.jmedchem.3c01872","volume":"67","author":"SM Szewczyk","year":"2024","unstructured":"Szewczyk, S. M., Verma, I., Edwards, J. T., Weiss, D. R. & Chekler, E. L. P. Trends in neosubstrate degradation by cereblon-based molecular glues and the development of novel multiparameter optimization scores. J. Med. Chem. 67, 1327\u20131335 (2024).","journal-title":"J. Med. Chem."},{"key":"70663_CR53","unstructured":"Axford, J. et al. Preparation of dihydropyrimidines as glue degraders for the treatment and prevention of diseases mediated by various target proteins. WO2021053555 (2021)."},{"key":"70663_CR54","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.celrep.2016.09.092","volume":"17","author":"MC Gundry","year":"2016","unstructured":"Gundry, M. C. et al. Highly efficient genome editing of murine and human hematopoietic progenitor cells by CRISPR\/Cas9. Cell Rep. 17, 1453\u20131461 (2016).","journal-title":"Cell Rep."},{"key":"70663_CR55","doi-asserted-by":"publisher","first-page":"360ra134","DOI":"10.1126\/scitranslmed.aaf9336","volume":"8","author":"MA DeWitt","year":"2016","unstructured":"DeWitt, M. A. et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells. Sci. Transl. Med. 8, 360ra134 (2016).","journal-title":"Sci. Transl. Med."},{"key":"70663_CR56","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nprot.2017.143","volume":"13","author":"RO Bak","year":"2018","unstructured":"Bak, R. O., Dever, D. P. & Porteus, M. H. CRISPR\/Cas9 genome editing in human hematopoietic stem cells. Nat. Protoc. 13, 358\u2013376 (2018).","journal-title":"Nat. Protoc."},{"key":"70663_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2022.100279","volume":"21","author":"P Skowronek","year":"2022","unstructured":"Skowronek, P. et al. Rapid and in-depth coverage of the (phospho-)proteome with deep libraries and optimal window design for dia-PASEF. Mol. Cell Proteomics 21, 100279 (2022).","journal-title":"Mol. Cell Proteomics"},{"key":"70663_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31492-0","volume":"13","author":"V Demichev","year":"2022","unstructured":"Demichev, V. et al. dia-PASEF data analysis using FragPipe and DIA-NN for deep proteomics of low sample amounts. Nat. Commun. 13, 3944 (2022).","journal-title":"Nat. Commun."},{"key":"70663_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbab041","volume":"2","author":"JP Quast","year":"2022","unstructured":"Quast, J. P., Schuster, D. & Picotti, P. protti: an R package for comprehensive data analysis of peptide- and protein-centric bottom-up proteomics data. Bioinform. Adv. 2, vbab041 (2022).","journal-title":"Bioinform. Adv."},{"key":"70663_CR60","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1021\/acs.jmedchem.3c02136","volume":"67","author":"SCC Lucas","year":"2024","unstructured":"Lucas, S. C. C. et al. Optimization of potent ligands for the E3 ligase DCAF15 and evaluation of their use in heterobifunctional degraders. J. Med. Chem. 67, 5538\u20135566 (2024).","journal-title":"J. Med. Chem."},{"key":"70663_CR61","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","volume":"14","author":"RP Nowak","year":"2018","unstructured":"Nowak, R. P. et al. Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat. Chem. Biol. 14, 706\u2013714 (2018).","journal-title":"Nat. Chem. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70663-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70663-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70663-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:03:19Z","timestamp":1779210199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70663-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70663"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70663-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: all the authors are or have been employed by AstraZeneca or Pharmaron. The synthesis of CRBN ligands and their associated CRBN binding data for compounds\n                      2, 3, 4, 5, 6, 8\n                      and\n                      12\n                      are reported in patent number: PCT\/EP2021\/076752 (WO2022069520); status of application: national phase applications pending; patent applicant: Astrazeneca AB; Inventors: Borjesson, Ulf; Perry, Matthew William Dampier; Grebner, Christoph; Michaelides, Iacovos Neal; Hayhow, Thomas George Christopher; Kettle, Jason Grant; Collie, Gavin William; Storer, Robert Ian; Bagal, Sharanjeet Kaur; Fallan, Charlene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4460"}}